Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study

Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis

(2020) Toshiki Kuno et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation

(2020) Thomas A. Mavrakanas et al.   Clinical Journal of the American Society of Nephrology

Warfarin use increases bleeding risk in hemodialysis patients with atrial fibrillation: A meta-analysis of cohort studies

(2019) Salman Hussain et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation Patients with Severe Kidney Disease or Undergoing Hemodialysis

(2019) Craig I. Coleman et al.   AMERICAN JOURNAL OF MEDICINE

Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease

(2019) Jeffrey T. Ha et al.   ANNALS OF INTERNAL MEDICINE

Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States

(2018) Konstantinos C. Siontis et al.   CIRCULATION

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

(2018) Jan Steffel et al.   EUROPACE

Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation

(2018) Yi-Cheng Lin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparison of Propensity Score Methods and Covariate Adjustment

(2017) Markus C. Elze et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation

(2017) Eleni Stamellou et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease

(2016) Khagendra Dahal et al.   CHEST

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians?

(2016) Tze-Fan Chao et al.   HEART RHYTHM

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients

(2015) An S. De Vriese et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis

(2015) K. E. Chan et al.   CIRCULATION

The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes

(2015) Peter C Austin et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis

(2014) Mitesh Shah et al.   CIRCULATION

Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation—A nation-wide database analyses

(2014) Jien-Jiun Chen et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial

(2013) S. Apostolakis et al.   EUROPEAN HEART JOURNAL

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation

(2012) Masatsugu Hori et al.   CIRCULATION JOURNAL

Roles of Coagulation Pathway and Factor Xa in the Progression of Diabetic Nephropathy in db/db Mice

(2011) Ayaka Sumi et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation

(2011) Alvaro Alonso et al.   CIRCULATION

Effectiveness and Safety of Warfarin Initiation in Older Hemodialysis Patients with Incident Atrial Fibrillation

(2011) W. C. Winkelmayer et al.   Clinical Journal of the American Society of Nephrology

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

(2011) K. A. A. Fox et al.   EUROPEAN HEART JOURNAL

Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation

(2011) Ricarda Marinigh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy

(2010) Volker Wizemann et al.   KIDNEY INTERNATIONAL

Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation

(2009) Alan S. Go et al.   CIRCULATION

Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation

(2009) K. E. Chan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE